Drugs for Pancreatic Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 330)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
2078-54-8 |
4943 |
Synonyms:
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Diisopropylphenol
2,6-diisopropylphenol|Diprivan®|ICI 35868
Abbott brand OF propofol
Alpha Brand OF propofol
Aquafol
Astra brand OF propofol
AstraZeneca brand OF propofol
Braun brand OF propofol
Curamed brand OF propofol
Diisopropylphenol
Diprivan
Disoprivan
Disoprofol
Fresenius brand OF propofol
Fresenius kabi brand OF propofol
Fresofol
ICI 35868
ICI 35-868
|
ICI35,868
ICI-35868
Ivofol
Juste brand OF propofol
NSC-5105
Parnell brand OF propofol
Pisa brand OF propofol
Propofol
Propofol abbott
Propofol fresenius
Propofol MCT
Propofol rovi
Propofol-lipuro
Propofolum
Rapinovet
Recofol
Rovi brand OF propofol
Schering brand OF propofol
Zeneca brand OF propofol
|
|
2 |
|
Desflurane |
Approved |
Phase 4 |
|
57041-67-5 |
42113 |
Synonyms:
(+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
(±)-2-difluoromethyl 1,2,2,2-tetrafluoroethyl ether
1,1,1,2-Tetrafluoro-2-(difluoromethoxy)ethane
1,2,2,2-Tetrafluoroethyl difluoromethyl ether
Baxter anaesthesia brand OF desflurane
Baxter brand OF desflurane
DESFLURANE
DESFLURANO
Desflurano [INN-Spanish]
|
DESFLURANUM
Desfluranum [INN-Latin]
Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
HFE-236EA2
I-653
Ohmeda brand OF desflurane
Suprane
Zeneca brand OF desflurane
|
|
3 |
|
Anesthetics, Inhalation |
|
Phase 4 |
|
|
|
4 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
5 |
|
Darbepoetin alfa |
Approved, Investigational |
Phase 2, Phase 3 |
|
209810-58-2 |
|
Synonyms:
ARANESP
ARANESP SURECLICK
Darbepoetin
DARBEPOETIN ALFA
Darbepoetin alfa,recombinant
Darbepoetina alfa
|
EPOETIN
ERYTHROPOIETIN PRECURSOR
KRN321
KRN-321
NESP
|
|
6 |
|
Asparaginase Escherichia coli |
Approved, Investigational |
Phase 3 |
|
9015-68-3 |
|
Synonyms:
ASPARAGINASE
Asparaginase (E. coli)
COLASPASE
CRASNITIN
ELSPAR
|
Escherichia coli L-asparaginase
L-ASPARAGINASE
L-asparagine amidohydrolase
NSC-109229
Putative L-asparaginase precursor
|
|
7 |
|
Epirubicin |
Approved |
Phase 2, Phase 3 |
|
56420-45-2 |
41867 |
Synonyms:
4' Epi adriamycin
4' Epi doxorubicin
4' Epi DXR
4' Epiadriamycin
4' Epidoxorubicin
4'-Epiadriamycin
4'-Epi-adriamycin
4'-Epidoxorubicin
4'-Epi-doxorubicin
4'-Epi-DXR
Cell pharm brand OF epirubicin
Ellence
EPI cell
Epiadriamycin
EPIcell
EPI-cell
Epidoxorubicin
Epi-Dx
Epilem
Epirubicin
Epirubicin hydrochloride
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
|
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin
Farmorubicina
Farmorubicine
Hydrochloride, epirubicin
IMI 28
IMI28
IMI-28
Kenfarma brand OF epirubicin hydrochloride
Lemery brand OF epirubicin hydrochloride
NSC-256942
Pfizer brand OF epirubicin hydrochloride
Pharmorubicin
Pharmorubicin Pfs
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
|
|
8 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
9 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
10 |
|
Phenytoin |
Approved, Vet_approved |
Phase 3 |
|
57-41-0 |
1775 |
Synonyms:
5,5-Diphenylhydantoin
5,5-Diphenylimidazolidine-2,4-dione
5,5-Diphenyl-imidazolidine-2,4-dione
5,5-Diphenyltetrahydro-1H-2,4-imidazoledione
5,5-Dwufenylohydantoina
Aleviatin
Antisacer
Auranile
Causoin
Citrullamon
Citrulliamon
Comital
Comitoina
Convul
Danten
Dantinal
Dantoinal
Dantoinal klinos
Dantoine
Denyl
Didan TDC 250
Difenilhidantoina
Difenilhidantoina [Spanish]
Difenin
Difetoin
Difhydan
Dihycon
Dihydan
Di-Hydan
Dihydantoin
DILABID
Di-Lan
DILANTIN
Dilantin acid
Dilantin®|Epanutin®|Phenytex®|phenytoin sodium
DILANTIN-125
DILANTIN-30
Dilantine
Dillantin
Dintoin
Dintoina
Diphantoin
Diphedal
Diphedan
Diphenat
Diphenin
Diphenine
Diphentoin
Diphentyn
Diphenylan
Diphenylan sodium
Diphenylhydantoin
Diphenylhydantoinate, sodium
Diphenylhydantoine [French]
Diphenylhydatanoin
Di-Phetine
Ditoinate
DPH
Ekko
Elepsindon
Enkelfel
Epamin
Epanutin
Epasmir 5
Epdantoin Simple
Epdantoine simple
Epelin
Epifenyl
Epihydan
Epilan
Epilan D
Epilan-D
Epilantin
Epinat
Epised
Eptal
Eptoin
Fenantoin
Fenidantoin s
Fenitoin
Fenitoina
Fenitoina [INN-Spanish]
|
Fentoin
Fenylepsin
Fenytoin Dak
Fenytoine
Gerot-epilan-D
Hidan
Hidantal
Hidantilo
Hidantina
Hidantina senosian
Hidantina vitoria
Hidantomin
Hindatal
Hydantal
Hydantin
Hydantoin
Hydantoinal
Hydantol
Ictalis simple
Idantoil
Idantoin
Iphenylhydantoin
Kessodanten
Labopal
Lehydan
Lepitoin
Lepsin
Mesantoin
Minetoin
Neos-Hidantoina
Neosidantoina
Novantoina
Novophenytoin
NSC-8722
Om hidantoina simple
Om-Hydantoine
Oxylan
Park davis brand OF phenytoin
Pfizer brand OF phenytoin
Phanantin
Phanatine
Phenatine
Phenatoine
Phenhydan
Phenhydanin
Phenitoin
Phentoin
PHENTYTOIN
PHENYTEK
PHENYTEX
Phenytoin
Phenytoin AWD
Phenytoin pfizer brand
Phenytoin phizer brand
Phenytoin sodium
Phenytoine
Phenytoine [INN-French]
Phenytoin-Gerot
Phenytoinum
Phenytoinum [INN-Latin]
Phizer brand OF phenytoin
Prompt Phenytoin Sodium
Ritmenal
Saceril
Sanepil
Silantin
Sinergina
SM-88 COMPONENT PHENYTOIN
Sodanthon
Sodantoin
Sodanton
Sodium diphenylhydantoinate
Solantin
Solantoin
Solantyl
Sylantoic
Tacosal
Thilophenyl
TOIN
Toin unicelles
Zentronal
Zentropil
|
|
11 |
|
Methoxsalen |
Approved |
Phase 3 |
|
298-81-7 |
4114 |
Synonyms:
6,7-FUROCOUMARIN
6-Hydroxy-7-methoxy-5-benzofuranacrylate delta-lactone
6-Hydroxy-7-methoxy-5-benzofuranacrylate δ-lactone
6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone
6-Hydroxy-7-methoxy-5-benzofuranacrylic acid δ-lactone
8 Methoxypsoralen
8 MOP
8-Methoxy-[furano-3'.2':6.7-coumarin]
8-Methoxy-2',3',6,7-furocoumarin
8-Methoxy-4',5':6,7-furocoumarin
8-Methoxyfuranocoumarin
8-Methoxypsoralen
8MOP
8-MOP
8-MP
9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one
Ammodin
Ammoidin
Boehringer ingelheim brand OF methoxsalen
Canderm brand OF methoxsalen
Chinoin brand OF methoxsalen
DB Brand OF methoxsalen
Delta Brand OF methoxsalen
Deltasoralen
Dermatech brand OF methoxsalen
Dermox
Galderma brand OF methoxsalen
Geroxalen
ICN brand 1 OF methoxsalen
ICN brand 2 OF methoxsalen
ICN brand 3 OF methoxsalen
Meladinin
Meladinina
Meladinine
Méladinine
Meladoxen
Meloxine
Methoxa dome
Methoxa-dome
|
Methoxalen
Methoxaten
METHOXSALEN
Methoxsalen canderm brand
Methoxsalen chinoin brand
Methoxsalen Delta brand
Methoxsalen dermatech brand
Methoxsalen mex-america brand
Methoxsalen sanofi-synthelabo brand
MÉTHOXSALÈNE
Metoxaleno
Mex america brand OF methoxsalen
Mex-america brand OF methoxsalen
New-Meladinin
NSC-45923
O-Methylxanthotoxol
Oxoralen
Oxsoralen
Oxsoralen Lotion
Oxsoralen ultra
Oxsoralen-ultra
Oxypsoralen
Proralone-Mop
Psoralen-Mop
Puvalen
Puvamet
PUVASORALEN-8
Sanofi synthelabo brand OF methoxsalen
Sanofi-synthelabo brand OF methoxsalen
SM-88 COMPONENT METHOXSALEN
Ultra mop
Ultramop
Ultramop Lotion
Uvadex
Xanthotoxin
Xanthotoxine
Xanthoxin
Zanthotoxin
|
|
12 |
|
Olaparib |
Approved |
Phase 3 |
|
763113-22-0 |
23725625 |
Synonyms:
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
AZ2281
AZ-2281
AZD2281
AZD-2281
AZD-2281|AZD2281|Lynparza®
|
KEYLYNK-010 COMPONENT OLAPARIB
KU-0059436
KU59436
KU-59436
Lynparza
OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
|
|
13 |
|
Atezolizumab |
Approved, Investigational |
Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
14 |
|
Asparagine |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
70-47-3 |
6267 |
Synonyms:
(-)-Asparagine
(2S)-2,4-Diamino-4-oxobutanoate
(2S)-2,4-diamino-4-oxobutanoic acid
(2S)-2-Amino-3-carbamoylpropanoate
(2S)-2-amino-3-carbamoylpropanoic acid
(S)-2,4-Diamino-4-oxobutanoate
(S)-2,4-Diamino-4-oxobutanoic acid
(S)-2-Amino-3-carbamoylpropanoate
(S)-2-amino-3-carbamoylpropanoic acid
(S)-Asparagine
2-Aminosuccinamate
2-Aminosuccinamic acid
a-Aminosuccinamate
a-Aminosuccinamic acid
Agedoite
alpha Amminosuccinamate
alpha Amminosuccinamic acid
alpha-Aminosuccinamate
alpha-aminosuccinamic acid
Altheine
Asn
Asparagine
Asparagine acid
Asparamide
Aspartamate
|
Aspartamic acid
Aspartic acid amide
Aspartic acid b-amide
Aspartic acid beta amide
b2,4-(S)-Diamino-4-oxo-utanoate
b2,4-(S)-Diamino-4-oxo-utanoic acid
Crystal VI
L-2,4-Diamino-4-oxobutanoate
L-2,4-Diamino-4-oxobutanoic acid
L-2-Aminosuccinamate
L-2-aminosuccinamic acid
L-Asparagin
L-Asparagine
L-Aspartamine
L-Aspartate b-amide
L-Aspartate beta-amide
L-Aspartate β-amide
L-Aspartic acid b-amide
L-aspartic acid beta-amide
L-aspartic acid β-amide
L-b-Asparagine
L-beta-Asparagine
N
Α-aminosuccinamate
α-aminosuccinamic acid
|
|
15 |
|
Irofulven |
Investigational |
Phase 3 |
|
158440-71-2 |
3844471 148189 |
Synonyms:
6-HYDROXYMETHYLACYLFULVENE
HMAF
IROFULVEN
|
|
|
16 |
|
Chrysarobin |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Hematinics |
|
Phase 3 |
|
|
|
18 |
|
ON 01910 |
|
Phase 3 |
|
|
|
19 |
|
Formyltetrahydrofolates |
|
Phase 3 |
|
|
|
20 |
|
Tetrahydrofolates |
|
Phase 3 |
|
|
|
21 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
22 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
23 |
|
Poly(ADP-ribose) Polymerase Inhibitors |
|
Phase 3 |
|
|
|
24 |
|
topoisomerase I inhibitors |
|
Phase 3 |
|
|
|
25 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
26 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
27 |
|
Endothelial Growth Factors |
|
Phase 3 |
|
|
|
28 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
29 |
|
Antibodies, Monoclonal |
|
Phase 3 |
|
|
|
30 |
|
Antibodies |
|
Phase 3 |
|
|
|
31 |
|
Calcium |
Nutraceutical |
Phase 3 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
32 |
|
Tegafur |
Approved, Investigational |
Phase 2 |
|
17902-23-7 |
5386 |
Synonyms:
1-(2-Tetrahydrofuryl)-5-fluorouracil
1-(Tetrahydro-2-furanyl)-5-fluorouracil
5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione
Atillon
CITOFUR
Florafur
Fluorofur
FT-207
Ftorafur
|
Futraful
MJF-12264
N1-(2'-Tetrahydrofuryl)-5-fluorouracil
NSC-148958
Sunfural S
TEGAFUR
Uftoral
Utefos
|
|
33 |
|
Metformin |
Approved |
Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
34 |
|
Everolimus |
Approved |
Phase 1, Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
35 |
|
Sirolimus |
Approved, Investigational |
Phase 1, Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
36 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
37 |
|
Trastuzumab |
Approved, Investigational |
Phase 2 |
|
180288-69-1 |
|
Synonyms:
4D5V8
ABP 980
ABP-980
ANTI HER2
D5v8|Herceptin®|R-597
DMB-3111 (TRASTUZUMAB BIOSIMILAR)
EG12014
EG-12014
HERCEPTIN
IG GAMMA-1 CHAIN C REGION
KADCYLA
|
R-597
RHUMAB HER2
SYD977
SYD-977
TRASTUZUMAB
TRASTUZUMAB BETA
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
38 |
|
Dasatinib |
Approved, Investigational |
Phase 2 |
|
302962-49-8 |
3062316 |
Synonyms:
(18F)-N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Anh. dasatinib
Anhydrous dasatinib
BMS 345825
BMS 345825|BMS 354825|BMS 35482513|Sprycel®
BMS 354825
BMS 35482513
BMS Dasatinib
BMS-354825
BMS-354825 HYDRATE
BMS-354825-03
|
DASATINIB
Dasatinib (anh.)
dasatinib (anhydrous)
DASATINIB ANHYDROUS
DASATINIB HYDRATE
DASATINIB MONOHYDRATE
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel
|
|
39 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
40 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
41 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 2 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
42 |
|
Docetaxel |
Approved, Investigational |
Phase 1, Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
43 |
|
Heparin, bovine |
Approved, Investigational, Withdrawn |
Phase 2 |
|
9005-49-6 |
22833565 9812414 772 |
Synonyms:
Adomiparin
alpha-Heparin
Ariven
Arteven
Bemiparin
BOVINE HEPARIN
Calcilean
CALCIPARINE
Certoparin
CLEXANE
Clexane®|enoxaparin sodium|Lovenox®|PK-10169|RP-54563
Clivarin
Clivarine
DALTEPARIININATRIUM
Dalteparin
DALTEPARIN SODIUM
dalteparin sodium|Fragmin®
DALTEPARIN SODNÁ SÅ®L
DALTEPARIN SODYUM
DALTEPARINA SODICA
DALTEPARINA SÓDICA
DALTEPARINE SODIQUE
DALTÉPARINE SODIQUE
DALTEPARINNATRIUM
DALTEPARIN-NATRIUM
DALTEPARIN-NÁTRIUM
DALTEPARINO NATRIO DRUSKA
DALTEPARINUM NATRICUM
DALTEPARYNA SODOWA
Depo-Heparin
ENOXAPARIN
ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE)
ENOXAPARIN SODIUM SALT
Eparina
Eparina [DCIT]
Fluxum
FR-860
FRAGMIN
Fragmin A
Fragmin B
Fraxiparin
Hed-Heparin
Hepalean
HEPARIN
Heparin Cy 216
|
HEPARIN FRAGMENT KABI 2165
Heparin Leo
Heparin Lock Flush
HEPARIN SODIUM
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparina
HEPARINATE
Heparine
HEPARINIC ACID
Heparinsodiumsalt
Heparinum
Hepathrom
HepFlush®
HEP-LOCK
KABI-2165
Leparan
Lipo-Hepin
LIQUAEMIN
Liquaemin Sodium
Liquemin
LOVENOX
LOVENOX (PRESERVATIVE FREE)
LOW LIQUEMINE
Low molecular weight heparin sodium
Multiparin
Novoheparin
Pabyrin
PANHEPRIN
Parnaparin
Parnaparin sodium
Parvoparin
PK-10169
Pularin
Reviparin
RP-54563
Sandoparin
SODIUM HEPARIN
Sublingula
TEDELPARIN
Thromboliquine
Unfractionated heparin
Vetren
Vitrum AB
|
|
44 |
|
Reviparin |
Approved, Investigational |
Phase 2 |
|
9041-08-1 |
|
Synonyms:
INNOHEP
Innohep®|tinzaparin sodium
LNH1
LNH-1
LOGIPARIN
|
Reviparin sodium
TINZAPARIN
Tinzaparin sodium
Tinzaparina
|
|
45 |
|
Sargramostim |
Approved, Investigational |
Phase 1, Phase 2 |
|
123774-72-1 |
|
Synonyms:
B1 61.012
B1-61012
LEUKINE
RECOMBINANT GM-CSF
Recombinant human granulocyte-macrophage colony stimulating factor
|
rGM-CSF
RHU GM-CSF
RHU-GM-CSF
SARGRAMOSTIM
|
|
46 |
|
Dipyridamole |
Approved |
Phase 2 |
|
58-32-2 |
3108 |
Synonyms:
Antistenocardin
Apo dipyridamole
Apo-dipyridamole
Apotex brand OF dipyridamole
Ashbourne brand OF dipyridamole
ATTIA
B01AC07
Belmac brand OF dipyridamole
Berlin chemie brand OF dipyridamole
Berlin-chemie brand OF dipyridamole
Boehringer ingelheim brand OF dipyridamole
Cardoxin
Cerebrovase
CEREBROVASE 100
CEREBROVASE 25
Cléridium
Cleridium 150
Curantil
Curantyl
Dipiridamol
Dipyramidole
Dipyridamine
Dipyridamol
|
DIPYRIDAMOLE
Dipyridamolum
Dipyudamine
Dypyridamol
IPRAD brand OF dipyridamole
IV PERSANTINE
Kurantil
Miosen
MODAPLATE
Novo dipiradol
Novo-dipiradol
Novopharm brand OF dipyridamole
NSC-515776
OFCRAM PR
Persantin
PERSANTIN RET
Persantine
Persantine®
PYRIDANTIN
RA-8
Usaf ge-12
VASYROL
|
|
47 |
|
Etanercept |
Approved, Investigational |
Phase 1, Phase 2 |
|
185243-69-0 |
|
Synonyms:
BENEPALI
CD120B
ENBREL
Enbrel Sureclick
Etanercept
etanercept-szzs
etanercept-ykro
FC
GP2015
GP-2015
GP2015C
HD203
L04AB01
|
LBEC0101
P75
P80 TNF-ALPHA RECEPTOR
Recombinant human TNF
RHU TNFR
rhu TNFR:Fc
rhu-TNFR:Fc
TNF-R2
TNFR-Immunoadhesin
TUMOR NECROSIS FACTOR RECEPTOR 2
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1B PRECURSOR
TUMOR NECROSIS FACTOR RECEPTOR TYPE II
|
|
48 |
|
Trabectedin |
Approved, Investigational |
Phase 2 |
|
114899-77-3 |
108150 |
Synonyms:
Ect 743
Ecteinascidin
Ecteinascidin 743
ecteinascidin 743|ET-743|Yondelis®
ECTEINASCIDINS TRABECTEDIN
ET743
|
ET-743
NSC 684766
NSC-648766
Trabectedin
Trabectedina
Yondelis
|
|
49 |
|
Cobalt |
Approved, Experimental, Withdrawn |
Phase 2 |
|
7440-48-4 |
104729 |
Synonyms:
Aquacat
Co
Co(2+)
Co(II)
CO2+
Cobalt
COBALT (II) ion
Cobalt(2+)
Cobalt(2+) ion
|
Cobalt(II) cation
Cobalt, elemental
Cobalt-59
Cobalto
Cobaltous ion
Cobaltum
Cobatope-57
Kobalt
Super cobalt
|
|
50 |
|
Aldesleukin |
Approved |
Phase 1, Phase 2 |
|
110942-02-4 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukin
Aldesleukina
IL-2
ILT101
ILT-101
Interleukin-2 aldesleukin
|
INTERLEUKIN-2 PRECURSOR
Interleukin-2(2-133),125-ser
Recombinant human interleukin-2
Recombinant interleukin-2 human
T-CELL GROWTH FACTOR
TCGF
|
|
Interventional clinical trials:
(show top 50)
(show all 741)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer |
Unknown status |
NCT03401827 |
Phase 4 |
Chemotherapy (Gemcitabine + nab-paclitaxel) |
2 |
A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma |
Completed |
NCT00854477 |
Phase 4 |
capecitabine |
3 |
Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? |
Completed |
NCT02335151 |
Phase 4 |
Desflurane |
4 |
Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study |
Completed |
NCT00578279 |
Phase 4 |
dehydrated alcohol |
5 |
A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma |
Withdrawn |
NCT03891979 |
Phase 4 |
Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29 |
6 |
Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy |
Withdrawn |
NCT01401387 |
Phase 4 |
|
7 |
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. |
Unknown status |
NCT02072616 |
Phase 3 |
|
8 |
Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma |
Unknown status |
NCT01065870 |
Phase 2, Phase 3 |
Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy |
9 |
A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Plus Capecitabine (Arm GC) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH) |
Unknown status |
NCT01077427 |
Phase 3 |
Gemcitabine + Capecitabine |
10 |
A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVACâ„¢-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen |
Unknown status |
NCT00088660 |
Phase 3 |
|
11 |
A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma |
Completed |
NCT02993731 |
Phase 3 |
Napabucasin;Nab-paclitaxel;Gemcitabine |
12 |
Phase II/III of Randomized Controlled Clinical Research on Irreversible Electroporation Synchronous Chemotherapy for Locally Advanced Pancreatic Adenocarcinoma |
Completed |
NCT03673137 |
Phase 2, Phase 3 |
Gemcitabine |
13 |
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma |
Completed |
NCT01964430 |
Phase 3 |
nab-Paclitaxel;Gemcitabine |
14 |
Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma |
Completed |
NCT00033735 |
Phase 3 |
fluorouracil;Irofulven |
15 |
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine |
Completed |
NCT00099294 |
Phase 3 |
Glufosfamide |
16 |
Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil |
Completed |
NCT00960284 |
Phase 2, Phase 3 |
capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride |
17 |
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma |
Completed |
NCT03665441 |
Phase 3 |
eryaspase;Gemcitabine plus Abraxane;Irinotecan plus 5-FU plus leucovorin |
18 |
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma |
Completed |
NCT02436668 |
Phase 3 |
Ibrutinib;Gemcitabine;Nab-paclitaxel |
19 |
A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma |
Completed |
NCT00003216 |
Phase 3 |
fluorouracil;gemcitabine hydrochloride |
20 |
Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma |
Completed |
NCT01526135 |
Phase 3 |
mFolfirinox;Gemcitabine |
21 |
A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma |
Completed |
NCT01746979 |
Phase 3 |
TH-302;Gemcitabine;Placebo (5 percent dextrose - D5W) |
22 |
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment |
Completed |
NCT03126435 |
Phase 3 |
EndoTAG-1;Gemcitabine |
23 |
A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma |
Completed |
NCT03943667 |
Phase 3 |
Gemcitabine;Paclitaxel |
24 |
A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer |
Completed |
NCT01360853 |
Phase 3 |
ON 01910.Na;Gemcitabine |
25 |
A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer |
Completed |
NCT00088894 |
Phase 3 |
gemcitabine hydrochloride |
26 |
A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas |
Completed |
NCT00844649 |
Phase 3 |
Albumin-bound paclitaxel (ABI-007);Gemcitabine |
27 |
Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib. Intergroup Study |
Completed |
NCT00634725 |
Phase 3 |
capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride |
28 |
Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4) |
Completed |
NCT00044031 |
Phase 3 |
|
29 |
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas |
Completed |
NCT03504423 |
Phase 3 |
CPI 613, mFolfirinox;Folfirinox |
30 |
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine |
Recruiting |
NCT01954992 |
Phase 3 |
Glufosfamide;Fluorouracil |
31 |
A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma |
Recruiting |
NCT03899636 |
Phase 3 |
Modified FOLFIRINOX Regimen |
32 |
Randomized Phase 3 Trial Comparing FOLFOX to Gemcitabine in Metastatic First-line in Patients With Pancreatic Adenocarcinoma and Non-fit for FOLFIRINOX |
Recruiting |
NCT04167007 |
Phase 3 |
Gemcitabine;FOLFOX |
33 |
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma |
Recruiting |
NCT03377491 |
Phase 3 |
Gemcitabine;nab paclitaxel |
34 |
A Phase â…¢, Randomized Controlled Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine Versus mFOLFIRINOX in Treating Patients With Borderline Reseactable and Locally Advanced Pancreatic Cancer |
Recruiting |
NCT04617821 |
Phase 3 |
Nab paclitaxel plus gemcitabine;mFOLFIRINOX |
35 |
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer |
Recruiting |
NCT04340141 |
Phase 3 |
Oxaliplatin;Irinotecan Hydrochloride;Leucovorin Calcium;Fluorouracil |
36 |
Precision Promise Platform Trial for Metastatic Pancreatic Cancer |
Recruiting |
NCT04229004 |
Phase 3 |
Gemcitabine combined with nab-paclitaxel;Dose -mFOLFIRINOX;Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel;Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine;Drug: Dose -SM-88 |
37 |
Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study |
Recruiting |
NCT04927780 |
Phase 3 |
Leucovorin Calcium;Fluorouracil;Irinotecan Hydrochloride;Oxaliplatin |
38 |
Neoadjuvant Chemotherapy for Pancreatic Cancer; GS vs. GnP |
Recruiting |
NCT05268692 |
Phase 2, Phase 3 |
GS;GnP |
39 |
Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors |
Recruiting |
NCT05181605 |
Phase 2, Phase 3 |
Folfirinox and Stereotactic Body Radiotherapy |
40 |
Intrabdominal Hyperthermic Chemotherapy Using Gemcitabine to Treat Pancreatic Carcinomatosis |
Recruiting |
NCT03251365 |
Phase 2, Phase 3 |
HIPEC-gemcitabine |
41 |
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas |
Active, not recruiting |
NCT04083235 |
Phase 3 |
Irinotecan Liposomal Injection;Oxaliplatin;5Fluorouracil;Leucovorin;Nab-paclitaxel;Gemcitabine |
42 |
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy |
Active, not recruiting |
NCT02184195 |
Phase 3 |
Olaparib;Placebo |
43 |
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma |
Active, not recruiting |
NCT01013649 |
Phase 3 |
Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride |
44 |
A Phase III, Multicenter, Prospective, Randomized, Patients With Resectable Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. |
Not yet recruiting |
NCT04835064 |
Phase 3 |
Nab paclitaxel;Gemcitabine;mFOLFIRINOX |
45 |
Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease |
Not yet recruiting |
NCT05482516 |
Phase 3 |
Atezolizumab;Bevacizumab |
46 |
Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma |
Terminated |
NCT01900327 |
Phase 3 |
Gemcitabine neoadjuvant;Gemcitabine adjuvant |
47 |
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1) |
Terminated |
NCT01956812 |
Phase 3 |
IMMU-107;placebo;Gemcitabine |
48 |
Neoadjuvant Radiotherapy in Patients With Primary Resectable Adenocarcinoma of the Pancreatic Head Plus Adjuvant Chemotherapy: a Randomized Controlled Phase III Trial |
Terminated |
NCT01419002 |
Phase 3 |
|
49 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas |
Terminated |
NCT01231347 |
Phase 3 |
AMG 479;Placebo;gemcitabine |
50 |
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study) |
Terminated |
NCT02119663 |
Phase 3 |
Ruxolitinib;Placebo;Capecitabine |
|